DOES CYCLOSPORINE INCREASE LIPOPROTEIN(A) CONCENTRATIONS IN RENAL-TRANSPLANT RECIPIENTS

被引:84
作者
WEBB, AT [1 ]
REAVELEY, DA [1 ]
ODONNELL, M [1 ]
OCONNOR, B [1 ]
SEED, M [1 ]
BROWN, EA [1 ]
机构
[1] CHARING CROSS HOSP,CHARING CROSS & WESTMINSTER MED SCH,DEPT CHEM PATHOL,LONDON W6 8RF,ENGLAND
关键词
D O I
10.1016/0140-6736(93)92616-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cyclosporin, the immunosuppressant of choice for renal transplant recipients, has been implicated as the cause of abnormalities in serum lipid concentrations in these patients. We have measured serum lipoprotein(a) concentrations and analysed the distribution of apoprotein(a) isoforms in 90 renal transplant recipients receiving cyclosporin and prednisolone (with or without azathioprine), 59 patients receiving azathioprine and prednisolone alone, and 146 non-hyperlipidaemic controls. Cyclosporin-treated patients had significantly higher lipoprotein(a) concentrations (median 170 [interquartile range 55-382] mg/L) than those receiving azathioprine and prednisolone (64 [10-204] mg/L, p = 0.001 ) or the healthy controls (94 [18-280] mg/L, p = 0.008). The difference between the azathioprine and prednisolone group and the controls was not significant. Although the time since transplantation was significantly shorter for the cyclosporin-treated group, there was no correlation between lipoprotein(a) concentration and time since transplantation (r = -0.13, p = 0.18). Apoprotein(a) phenotyping showed no significant differences in the distribution of apoprotein(a) isoforms between the treatment groups or between patient and control groups. Lipoprotein(a) concentrations are higher in renal transplant recipients treated with cyclosporin than in those maintained on azathioprine and prednisolone. The mechanisms underlying this abnormality remain to be elucidated.
引用
收藏
页码:268 / 270
页数:3
相关论文
共 22 条
[1]  
[Anonymous], 1956, NONPARAMETRIC STAT B
[2]   THE ASSOCIATION BETWEEN SERUM LP(A) CONCENTRATIONS AND ANGIOGRAPHICALLY ASSESSED CORONARY ATHEROSCLEROSIS - DEPENDENCE ON SERUM LDL LEVELS [J].
ARMSTRONG, VW ;
CREMER, P ;
EBERLE, E ;
MANKE, A ;
SCHULZE, F ;
WIELAND, H ;
KREUZER, H ;
SEIDEL, D .
ATHEROSCLEROSIS, 1986, 62 (03) :249-257
[3]   EFFECTS OF CYCLOSPORINE THERAPY ON PLASMA-LIPOPROTEIN LEVELS [J].
BALLANTYNE, CM ;
PODET, EJ ;
PATSCH, WP ;
HARATI, Y ;
APPEL, V ;
GOTTO, AM ;
YOUNG, JB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 262 (01) :53-56
[4]  
BLACK IW, 1992, CLIN CHEM, V38, P353
[5]   GENETICS OF THE QUANTITATIVE LP(A) LIPOPROTEIN TRAIT .3. CONTRIBUTION OF LP(A) GLYCOPROTEIN PHENOTYPES TO NORMAL LIPID VARIATION [J].
BOERWINKLE, E ;
MENZEL, HJ ;
KRAFT, HG ;
UTERMANN, G .
HUMAN GENETICS, 1989, 82 (01) :73-78
[6]  
CANAFAX DM, 1986, TRANSPLANT P, V18, P192
[7]   LIPOPROTEIN(A) AND APOLIPOPROTEIN CHANGES AFTER CARDIAC TRANSPLANTATION [J].
FARMER, JA ;
BALLANTYNE, CM ;
FRAZIER, OH ;
RADOVANCEVIC, B ;
PAYTONROSS, C ;
PATSCH, W ;
MORRISETT, JD ;
GOTTO, AM ;
YOUNG, JB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (04) :926-930
[8]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[9]  
GURECKI J, 1985, TRANSPLANT P, V17, P1997
[10]   ELEVATED LIPOPROTEIN(A) LEVELS IN RENAL-TRANSPLANTATION AND HEMODIALYSIS-PATIENTS [J].
HEIMANN, P ;
JOSEPHSON, MA ;
FELLNER, SK ;
THISTLETHWAITE, JR ;
STUART, FP ;
DASGUPTA, A .
AMERICAN JOURNAL OF NEPHROLOGY, 1991, 11 (06) :470-474